Table 3 |
||||||||
|
Summary of outcomes of studies of acetylcysteine for prevention of contrast-induced nephropathy. |
||||||||
|
First Author |
Contrast-induced nephropathy* |
Acetylcysteine Serum Creatinine (μmol/L) |
Control Serum Creatinine (μmol/L) |
Dialysis (N) |
||||
|
|
||||||||
|
Acetylcysteine |
Control |
Baseline |
Second SCr |
Baseline |
Second SCr |
NAC |
Control |
|
|
|
||||||||
|
Allaqaband25 |
8/45 (18%) |
6/40 (15%) |
194.5 |
196.3 |
179.5 |
179.5 |
2 |
0 |
|
Baker26 |
2/41 (5%) |
8/39 (21%) |
163.6 |
156.5 |
154.7 |
159.1 |
0 |
0 |
|
Briguori27 |
6/92 (7%) |
10/91 (11%) |
134.4 |
130.8 |
136.1 |
135.3 |
0 |
1 |
|
Diaz-Sandoval28 |
2/25 (8%) |
13/29 (45%) |
146.7 |
135.5 |
137.9 |
166.2 |
0 |
0 |
|
Durham29 |
10/38 (26%) |
9/41 (22%) |
194.5 |
NR |
203.3 |
NR |
NR |
NR |
|
Efrati30 |
0/24 (0%) |
2/25 (8%) |
135.3 |
143.2 |
131.7 |
143.2 |
0 |
0 |
|
Fung31 |
8/46 (17%) |
6/45 (13%) |
200.7 |
216.6 |
209.5 |
212.2 |
NR |
NR |
|
Goldenberg32 |
4/41 (10%) |
3/39 (8%) |
176.8 |
176.8 |
168.0 |
165.3 |
0 |
0 |
|
Kay33 |
4/102 (4%) |
12/98 (12%) |
119.3 |
107.8 |
120.2 |
122.0 |
0 |
0 |
|
Kefer34 |
2/53 (8%) |
3/51 (6%) |
91.9 |
91.1 |
102.5 |
93.7 |
0 |
0 |
|
MacNeill35 |
1/21 (5%) |
7/22 (32%) |
167.1 |
168.0 |
168.0 |
210.4 |
NR |
NR |
|
Oldemeyer36 |
4/49 (8%) |
3/47 (6%) |
144.1 |
NR |
146.7 |
NR |
0 |
0 |
|
Shyu37 |
2/60 (3%) |
15/61 (25%) |
247.5 |
221.0 |
247.5 |
274.0 |
0 |
1 |
|
Vallero38 |
4/47 (9%) |
4/53 (8%) |
87.5 |
93.7 |
84 |
86.6 |
NR |
NR |
|
|
||||||||
|
Legend: SCr = serum creatinine (for conversion to mg/dL divide by 88.4); NR = not recorded or available. *Values are numbers of patients with contrast-induced nephropathy/total number of patients in treatment group (%). |
||||||||
|
Bagshaw and Ghali BMC Medicine 2004 2:38 doi:10.1186/1741-7015-2-38 |
||||||||
